Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Transplantation
Volume 2017 (2017), Article ID 3197042, 6 pages
https://doi.org/10.1155/2017/3197042
Case Report

Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation

1Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France
2Department of Nephrology and Transplantation, University Hospital of Strasbourg, Strasbourg, France
3Université Paul Sabatier, Toulouse, France
4INSERM U1043, IFR-BMT, CHU Purpan, Toulouse, France

Correspondence should be addressed to Nassim Kamar; rf.esuoluot-uhc@n.ramak

Received 23 August 2017; Accepted 16 November 2017; Published 28 December 2017

Academic Editor: Ryszard Grenda

Copyright © 2017 Luca Lanfranco et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Kohei, T. Hirai, K. Omoto, H. Ishida, and K. Tanabe, “Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period,” American Journal of Transplantation, vol. 12, no. 2, pp. 469–476, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Opelz, C. Morath, C. Süsal, T. H. Tran, M. Zeier, and B. Döhler, “Three-year outcomes following 1420 ABO-incompatible living-donor kidney transplants performed after ABO antibody reduction: results from 101 centers,” Transplantation, vol. 99, no. 2, pp. 400–404, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Okumi, D. Toki, T. Nozaki et al., “ABO-Incompatible Living Kidney Transplants: Evolution of Outcomes and Immunosuppressive Management,” American Journal of Transplantation, vol. 16, no. 3, pp. 886–896, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. O. R. Blume, S. E. Yost, and B. Kaplan, “Antibody-mediated rejection: pathogenesis, prevention, treatment, and outcomes,” Journal of Transplantation, vol. 2012, Article ID 201754, 7 pages, 2012. View at Publisher · View at Google Scholar
  5. J. E. Locke, C. M. Magro, A. L. Singer et al., “The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection,” American Journal of Transplantation, vol. 9, no. 1, pp. 231–235, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. B. J. Orandi, A. A. Zachary, N. N. Dagher et al., “Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation,” Transplantation, vol. 98, no. 8, pp. 857–863, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Burbach, C. Suberbielle, I. Brochériou et al., “Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts,” Transplantation, vol. 98, no. 10, pp. 1056–1059, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. A.-R. Biglarnia, B. Nilsson, T. Nilsson et al., “Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation,” Transplant International, vol. 24, no. 8, pp. e61–e66, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. Z. A. Stewart, T. E. Collins, A. J. Schlueter et al., “Case report: eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant,” Transplantation Proceedings, vol. 44, no. 10, pp. 3033–3036, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. V. Frémeaux-Bacchi and C. M. Legendre, “The emerging role of complement inhibitors in transplantation,” Kidney International, vol. 88, no. 5, pp. 967–973, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. M. D. Stegall, T. Diwan, S. Raghavaiah, L. D. Cornell, J. Burns, and P. G. Dean, “Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients,” American Journal of Transplantation, vol. 11, no. 11, pp. 2405–2413, 2011. View at Google Scholar
  12. L. D. Cornell, C. A. Schinstock, M. J. Gandhi, W. K. Kremers, and M. D. Stegall, “Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year,” American Journal of Transplantation, vol. 15, no. 5, pp. 1293–1302, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. C. A. Irving, A. R. Gennery, V. Carter et al., “ABO-incompatible cardiac transplantation in pediatric patients with high isohemagglutinin titers,” The Journal of Heart and Lung Transplantation, vol. 34, no. 8, article no. 5994, pp. 1095–1102, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Weinstock, R. Möhle, C. Dorn et al., “Successful use of eculizumab for treatment of an acute hemolytic reaction after ABO-incompatible red blood cell transfusion,” Transfusion, vol. 55, no. 3, pp. 605–610, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. C. R. Fata, E. A. Gehrie, and P. P. Young, “Eculizumab inhibits hemolysis in a model of ABO-incompatible red blood cell transfusion,” Transfusion, vol. 55, no. 7, pp. 1823-1824, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Ikeda, M. Okumi, K. Unagami et al., “Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab,” Nephrology, vol. 21, pp. 35–40, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. C. M. Legendre, C. Licht, P. Muus et al., “Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome,” The New England Journal of Medicine, vol. 368, no. 23, pp. 2169–2181, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Bentall, D. B. Tyan, F. Sequeira et al., “Antibody-mediated rejection despite inhibition of terminal complement,” Transplant International, vol. 27, no. 12, pp. 1235–1243, 2014. View at Publisher · View at Google Scholar · View at Scopus